Conditions: Ovarian Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
In this study the investigators will be using an AUC of 6 based on creatinine clearance using the Carboplatin dosing formula used for Gynecologic Oncology Group protocols.

Given that myelosuppression was significant using the docetaxel dose of 75 mg/m\*2 in the SCOTROC trial, the prophylactic use of pegylated G-CSF in this Phase II trial is warranted. The expectation would be that patients will be able to receive their cycles in a more timely fashion, with less delays, thereby allowing for improved outcomes and decreased hospitalizations due to myelosuppression.

Detailed description:

Arms:
arm 1: * Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles
* Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles

Interventions: intervention 1: Docetaxel intervention 2: Carboplatin intervention 3: Pegylated G-CSF
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: